Myocardial nerve fibers are preserved in MPTP-treated mice, despite cardiac sympathetic dysfunction

Neuroscience Research

Volumn 60, Issue 3, 2008, Pages 314-318

  Amino, Takeshi ^a,b   Uchihara, Toshiki ^a   Tsunekawa, Hiroko ^d   Takahata, Kazue ^d   Shimazu, Seiichiro ^d   Mizusawa, Hidehiro ^b   Orimo, Satoshi ^a,c  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c The Mutualaid Association of Public School Teachers)   (Japan)

^d FP Pharmaceutical Corporation   (Japan)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydroxypyridine (MPTP); Cardiac sympathetic denervation; meta Iodobenzylguanidine (MIBG); Norepinephrine transporter; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; NORADRENALIN; NORADRENALIN TRANSPORTER; SYNAPTOPHYSIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; CONTROLLED STUDY; HEART MUSCLE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NERVE FIBER; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SYMPATHETIC FUNCTION; WESTERN BLOTTING;

ADRENERGIC FIBERS; ANIMALS; AUTONOMIC NERVOUS SYSTEM DISEASES; BLOTTING, WESTERN; DOPAMINE; HEART; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; SYNAPTOPHYSIN; TYROSINE 3-MONOOXYGENASE;

EID: 40649122979     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2007.11.011     Document Type: Article

References (19)

1. Amino T., Orimo S., Itoh Y., Takahashi A., Uchihara T., and Mizusawa H. Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol. 15 (2005) 29-34
2. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., and Kopin I.J. A primate model of Parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U.S.A. 80 (1983) 4546-4550
3. Fukumitsu N., Suzuki M., Fukuda T., Kiyono Y., Kajiyama S., and Saji H. Reduced 125I-meta-iodobenzylguanidine uptake and norepinephrine transporter density in the hearts of mice with MPTP-induced Parkinsonism. Nucl. Med. Biol. 33 (2006) 37-42
4. Heikkila R.E., and Sonsalla P.K. The MPTP-treated mouse as a model of Parkinsonism: how good is it?. Neurochem. Int. 20 Suppl. (1992) 299S-303S
5. Javitch J.A., D'Amato R.J., Strittmatter S.M., and Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. U.S.A. 82 (1985) 2173-2177
6. Jayanthi L.D., Annamalai B., Samuvel D.J., Gether U., and Ramamoorthy S. Phosphorylation of the norepinephrine transporter at threonine 258 and serine 259 is linked to protein kinase C-mediated transporter internalization. J. Biol. Chem. 281 (2006) 23326-23340
7. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
8. Li W., Knowlton D., Van Winkle D.M., and Habecker B.A. Infarction alters both the distribution and noradrenergic properties of cardiac sympathetic neurons. Am. J. Physiol. Heart Circ. Physiol. 286 (2004) H2229-H2236
9. Orimo S., Ozawa E., Nakade S., Hattori H., Tsuchiya K., Taki K., and Takahashi A. [123I]meta-iodobenzylguanidine myocardial scintigraphy differentiates corticobasal degeneration from Parkinson's disease. Intern. Med. 42 (2003) 127-128
10. Orimo S., Ozawa E., Nakade S., Sugimoto T., and Mizusawa H. (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 67 (1999) 189-194
11. Schroeter S., Apparsundaram S., Wiley R.G., Miner L.H., Sesack S.R., and Blakely R.D. Immunolocalization of the cocaine- and antidepressant-sensitive l-norepinephrine transporter. J. Comp. Neurol. 420 (2000) 211-232
12. Shimazu S., Takahata K., Tamashiro A., Yoneda F., Iida Y., and Saji H. Recovery of motor function and dopaminergic parameters in a mouse model of Parkinson's disease induced by co-administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate. J. Neural Transm. 110 (2003) 871-883
13. Sonsalla P.K., and Heikkila R.E. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur. J. Pharmacol. 129 (1986) 339-345
14. Sundström E., Strömberg I., Tsutsumi T., Olson L., and Jonsson G. Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res. 405 (1987) 26-38
15. Takahashi A. Autonomic nervous system disorders in Parkinson's disease. Eur. Neurol. 31 Suppl. (1991) 41-47
16. Takatsu H., Nishida H., Matsuo H., Watanabe S., Nagashima K., Wada H., Noda T., Nishigaki K., and Fujiwara H. Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG. J. Nucl. Med. 41 (2000) 71-77
17. Takatsu H., Wada H., Maekawa N., Takemura M., Saito K., and Fujiwara H. Significant reduction of 125 I-meta-iodobenzylguanidine accumulation directly caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine, a toxic agent for inducing experimental Parkinson's disease. Nucl. Med. Commun. 23 (2002) 161-166
18. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J. Neurol. Sci. 155 (1998) 60-67
19. Zigmond M.J., and Stricker E.M. Animal models of Parkinsonism using selective neurotoxins: clinical and basic implications. Int. Rev. Neurobiol. 31 (1989) 1-79